AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$NTHI

GARNETT KEITHLY sold $17K of NTHI

GARNETT KEITHLY (CFO) sold 5,000 shares of NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) at $3.36 on 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · GARNETT KEITHLY
Published Sep 19, 2026, 1:26 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 19, 2026, 1:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NTHI
Neutral
high confidence
Mentioned
$NTHI
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTHINeutralLow
01

Why it matters

The transaction is small and unlikely to affect market perception.

02

Market read

Minor insider sale with limited trading relevance.

03

What to watch

Potential upcoming corporate actions not disclosed in the filing.

Relevance 2/10Novelty 4/10Timing: filing date 2026-09-18

Background

Form 4 disclosures are primary sources for insider transactions.

Company-level read

Ticker impact

$NTHINeutralHigh confidence
Context

CFO Garnett Keithly sold 5,000 shares for $16,809 via a Form 4 filing.

Expected impact

No material impact

Evidence & confidence

Sale size is small relative to total holdings and market cap.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing, not a signal of weakness.

Key entities

  • Company
    Neonc Technologies Holdings, Inc.

    Issuer of the Form 4 filing.

  • Executive
    Garnett Keithly

    Chief Financial Officer of Neonc Technologies.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NTHI insider trading history →

Related articles

$NTHIMedAI 8/10

NeOnc Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NeOnc Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress Updated NEO100 Phase 1/2a results and NEO212 Phase 1 data to be presented at the Society for Neuro-Oncology Annual Meeting on November 13 CALABASAS, Calif., Nov.

SEC EDGAR 8-K
$NTHIMedAI 8/10

NeOnc to Present NEO100 and NEO212 Data at Neuro-Oncology Meeting

NeOnc Technologies (NTHI) will present data on its NEO100 and NEO212 programs at the Society for Neuro-Oncology meeting. NEO100 data includes Phase 1/2a study and compassionate use results for recurrent IDH1-mutant astrocytoma. NEO212 data covers Phase 1 safety, pharmacokinetics, and early activity signals in TMZ-resistant recurrent GBM and brain metastases. Both posters are scheduled for November 13, 2026.

tradingview.com
$NTHILowAI 8/10

NeOnc Reports Early Clinical Improvement in First Child Treated with NEO100 Under Compassionate Use in Abu Dhabi

NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 NeOnc Reports Early Clinical Improvement in First Child Treated with NEO100 Under Compassionate Use in Abu Dhabi Treating physicians report that a critically ill three-year-old boy is breathing independently and showing renewed movement following initiation of invest

SEC EDGAR 8-K